Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is well-positioned for future growth as it has a strong customer base and partnerships with big players in the healthcare industry. With a focus on expanding current customers and forming new partnerships, the company is experiencing moderate growth in customer additions and has a healthy backlog of revenue. Furthermore, their goal of reaching profitability by the second half of 2027, with a projected revenue of $109M in 2027, demonstrates the company's potential for financial success in the long term.

Bears say

Sophia Genetics is a healthcare technology company with a new exome product targeting germline diseases, and plans to offer this product for somatic diseases in the future. While the company's land and expand model is showing customer growth, it is not yet profitable and there is no guarantee of future profitability. Overall, SOPH must prove its ability to achieve profitability in the medium term, and its success in the competitive healthcare technology industry remains uncertain.

SOPH has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 2 analysts, SOPH has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.